Camurus AB (CAMX) AI Stock Analysis

• Market Cap: kr43.43B
• Dividend Yield: N/A
• Average Volume (3M): 66.74K
• Price to Earnings (P/E): 60.1
• Beta (1Y): 0.75
• Revenue Growth: 42.25%
• EPS Growth: 210.72%
• Country: SE
• Employees: 238
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): 4.08
• Shares Outstanding: 59,660,583
• 10 Day Avg. Volume: 74,292
• 30 Day Avg. Volume: 66,739
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr702.68
• Price Target Upside: -4.20% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: kr697.00 ▼(-4.98% Downside)

Camurus AB's overall stock score is driven primarily by its strong financial performance, characterized by robust revenue growth, high profitability, and efficient cash flow management. However, the technical analysis indicates some short-term weakness, and the high P/E ratio suggests potential overvaluation. The absence of earnings call data and corporate events means these factors did not influence the score.

Camurus AB Business Overview & Revenue Model

Company Description

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

How the Company Makes Money

Camurus AB generates revenue primarily through the commercialization of its products, including Buvidal, which is sold in various international markets. The company earns revenue from product sales, licensing agreements, and collaborations with pharmaceutical partners for the development and distribution of its drug formulations. Key revenue streams include royalties and milestones from partnerships, as well as direct sales from its proprietary drugs. Camurus has established significant partnerships with larger pharmaceutical companies, which provide not only financial support but also facilitate market access and distribution, thereby enhancing its earnings potential.

Camurus AB Financial Statement Overview

Summary

Camurus AB demonstrates strong financial health with robust revenue growth, high profitability, and efficient cash flow management. The company's low leverage and high return on equity further underscore its financial stability and operational efficiency. These strengths position Camurus AB well for future growth and resilience in the biotechnology industry.

Income Statement

Camurus AB has demonstrated strong revenue growth with a TTM revenue growth rate of 11.33%. The company maintains high profitability with a gross profit margin of 93.50% and a net profit margin of 31.69% in the TTM. The EBIT and EBITDA margins are also robust at 40.40% and 41.25%, respectively, indicating efficient operations. These metrics highlight the company's strong market position and operational efficiency.

Balance Sheet

The company exhibits a solid financial structure with a low debt-to-equity ratio of 0.027, suggesting minimal leverage and financial risk. The return on equity is healthy at 20.88%, reflecting effective use of equity to generate profits. The equity ratio stands at 87.50%, indicating a strong equity base relative to total assets, which enhances financial stability.

Cash Flow

Camurus AB shows impressive cash flow performance with a significant free cash flow growth rate of 68.47% in the TTM. The operating cash flow to net income ratio of 1.53 indicates strong cash generation relative to net income. The free cash flow to net income ratio of 0.88 further supports the company's ability to convert earnings into cash, which is crucial for sustaining operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.27B	1.87B	1.72B	956.34M	600.57M	336.00M
Gross Profit	2.12B	1.74B	1.59B	853.08M	515.22M	300.71M
EBITDA	934.93M	568.24M	562.54M	87.59M	-97.72M	-196.58M
Net Income	718.37M	428.39M	431.44M	55.55M	-90.45M	-167.26M
Balance Sheet
Total Assets	4.42B	3.76B	1.91B	1.31B	1.08B	1.04B
Cash, Cash Equivalents and Short-Term Investments	3.35B	2.85B	1.19B	565.54M	411.57M	461.79M
Total Debt	103.80M	17.04M	24.51M	26.22M	25.66M	25.48M
Total Liabilities	553.52M	467.33M	414.82M	310.82M	232.99M	196.66M
Stockholders Equity	3.87B	3.29B	1.49B	994.67M	848.91M	847.44M
Cash Flow
Free Cash Flow	618.96M	358.62M	596.75M	99.29M	-148.37M	-242.16M
Operating Cash Flow	706.33M	387.99M	606.88M	101.20M	-143.43M	-238.83M
Investing Cash Flow	-87.37M	-29.37M	-10.13M	5.38M	-4.94M	-3.33M
Financing Cash Flow	173.77M	1.30B	28.76M	43.70M	98.90M	347.85M

Camurus AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 733.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CAMX, the sentiment is Positive. The current price of 733.5 is above the 20-day moving average (MA) of 699.73, above the 50-day MA of 686.41, and above the 200-day MA of 612.07, indicating a bullish trend. The MACD of 16.34 indicates Negative momentum. The RSI at 69.72 is Neutral, neither overbought nor oversold. The STOCH value of 72.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CAMX.

Camurus AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAMX	67 Neutral	kr43.43B	60.10	20.47%	―	42.25%	210.72%
HNSA	56 Neutral	kr2.61B	―		―	20.12%	40.54%
Sector *	51 Neutral	$7.93B	-0.32	-43.43%	2.21%	22.30%	-1.88%
BOVNF	―	$200.55M	―	-28.70%	―	―	―
B9A	―	€2.33B	23.75	72.22%	―	―	―
6Y4	―	€259.41M	―	-55.23%	―	―	―
6XP	―	€180.65M	―	-41.54%	―	―	―

Camurus AB Corporate Events

Camurus Reports Robust Growth in Q2 2025

Camurus reported a successful second quarter in 2025, with total revenues increasing by 52% to SEK 676 million and profit before tax soaring by 195% to SEK 307 million. The company maintained its financial outlook for 2025 and highlighted key achievements such as a collaboration with Eli Lilly and Company, European Commission’s marketing authorization for Oczyesa®, and positive Phase 2b results for CAM2029. These developments underscore Camurus’ strong market positioning and potential for growth, benefiting stakeholders and reinforcing its leadership in the biopharmaceutical industry.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK750.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

Camurus’ Oczyesa Gains EU Approval for Acromegaly Treatment

Camurus announced that its product Oczyesa, a once-monthly subcutaneous octreotide, has received marketing authorization from the European Commission for treating acromegaly in adults. This approval marks a significant advancement as Oczyesa offers a convenient self-administration option and has shown superior biochemical control and improved quality of life in clinical trials, positioning Camurus as a leader in innovative treatments for rare diseases.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

Camurus Expands Share Count to Support Employee Incentive Program

Camurus AB announced an increase in the number of shares and votes following the exercise of employee stock options and the issuance of series C shares to fulfill commitments under its long-term incentive program. This move, which resulted in an increase of 781,566 shares and votes, reflects the company’s ongoing efforts to incentivize its employees and align with its strategic growth objectives.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

Camurus’ POSITANO Study Shows Promising Results for PLD Treatment

Camurus announced positive results from its POSITANO Phase 2b study, which evaluated the efficacy and safety of CAM2029 in patients with polycystic liver disease (PLD). The study demonstrated that CAM2029 significantly reduces liver and cyst volume compared to placebo and improves symptoms, addressing a high unmet medical need in PLD treatment. Following these results, Camurus plans to discuss a Phase 3 study with regulatory authorities, potentially enhancing its positioning in the biopharmaceutical industry and offering hope to PLD patients.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

Camurus Partners with Eli Lilly for Long-Acting Incretin Therapies

Camurus has entered a collaboration and license agreement with Eli Lilly, granting Lilly exclusive rights to develop and commercialize long-acting incretin products for cardiometabolic health using Camurus’ FluidCrystal technology. This partnership could bring Camurus up to $870 million in milestone payments and royalties, enhancing its market presence in the rapidly expanding field of metabolic diseases while allowing it to maintain its focus on CNS and rare diseases.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

Camurus Executes Share Repurchase to Support Incentive Plan

Camurus’ Board of Directors has exercised its authorization to repurchase shares as part of its commitment to the Performance Share Plan 2025/2028. This strategic move involves the repurchase and conversion of 240,000 series C shares into common shares, effectively doubling the company’s holdings of common shares to 480,000, which is expected to enhance the company’s operational flexibility and shareholder value.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

Camurus AB Annual General Meeting 2025: Key Resolutions and Strategic Initiatives

Camurus AB held its annual general meeting where key resolutions were passed, including the re-election of board members and the election of new members, as well as the approval of fees for board and committee members. The meeting also authorized the board to issue new shares and convertibles, acquire and transfer the company’s own shares, and implement a Performance Share Plan for employees. These resolutions aim to enhance Camurus’ strategic flexibility and align employee incentives with company performance, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

Camurus Reports Strong Q1 2025 Performance with Significant Revenue Growth

Camurus reported a strong first quarter in 2025, with total revenues increasing by 43% to SEK 558 million and product sales rising by 33% to SEK 485 million. The company also saw a significant 162% rise in profit before tax. Key developments included regulatory approval for Buvidal in Serbia and new launches in Switzerland and Luxembourg, along with the initiation of a Phase 1 clinical study for a new semaglutide depot. The positive CHMP opinion for Oczyesa® in the EU marks a significant advancement for Camurus, potentially enhancing its market positioning and stakeholder value.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK750.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

Camurus Appoints New CFO to Drive Growth and Diversification

Camurus has appointed Anders Vadsholt as its new Chief Financial Officer, effective July 1, 2025. Vadsholt brings significant financial and M&A experience from the biotech and pharmaceutical sectors, having previously served as CFO for Orphazyme A/S and Topotarget A/S. This strategic appointment is expected to support Camurus’ continued growth and diversification, enhancing its position in the biopharmaceutical industry. The transition is set to be smooth, with outgoing CFO Jon Garay Alonso remaining until August to facilitate the change.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.